Charles River Labs Balances Q1 Setback With 2H Rebound

Charles River Laboratories Intl ((CRL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Charles River Laboratories’ latest earnings call painted a cautiously optimistic picture as management weighed near-term pressure against a healthier medium-term setup. Organic revenue slipped and margins compressed in the first quarter, but strong bookings, an expanding backlog, targeted cost cuts and active portfolio reshaping helped underpin confidence in a second-half recovery and reaffirmed full-year guidance.

Q1 Revenue Growth Masks Organic Decline

Reported revenue reached $996 million in the first quarter of 2026, up 1.2% from a year earlier. Beneath the headline, organic revenue fell 1.5%, matching management’s prior outlook and underscoring the mixed demand backdrop across the company’s research and services portfolio.

Bookings and Backlog Support Future DSA Recovery

In the Discovery and Safety Assessment segment, a net book-to-bill ratio of 1.04 times and net bookings of $622 million exceeded the company’s threshold for healthy demand. The backlog in DSA edged up to $1.92 billion, giving management confidence that organic growth in this business should resume in the second half of the year.

Manufacturing Outperforms With Margin Gains

The Manufacturing segment delivered 2.9% organic revenue growth to $191 million, making it a relative bright spot. Operating margin in Manufacturing improved by 280 basis points to 25.9%, helped by robust demand for Microbial Solutions and the benefits of ongoing cost-saving initiatives.

Cost Savings Set Up Future Margin Expansion

Management outlined a clear cost-reduction path, targeting at least $100 million in incremental savings in 2026 on top of 2025 levels. When combined with previously announced actions, cumulative annualized savings are expected to exceed $300 million, providing a key lever for operating margin expansion despite flat-to-down revenue.

Portfolio Moves Aim to Strengthen Supply and Focus

The company continued to reshape its portfolio, acquiring K.F. Cambodia assets to tighten non-human primate supply and buying PathoQuest to enhance in vitro and next-generation sequencing capabilities. It also exited its CDMO and Cell Solutions businesses and plans to sell certain European discovery sites, a strategy aimed at sharpening focus and boosting margins over time.

Capital Returns Highlight Confidence in Strategy

Charles River deployed roughly $200 million to repurchase shares under its existing $1 billion authorization during the period. Management framed this buyback as part of a disciplined capital allocation approach and a signal of confidence in the long-term value of its strategy and balance sheet strength.

Guidance Holds Despite Lower Revenue Outlook

The company reaffirmed its 2026 organic revenue outlook, targeting a decline of 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30, implying mid- to high-single-digit growth versus 2025. Reported revenue is now expected to fall 4.0% to 5.5%, reflecting currency headwinds and the impact of divestitures, while free cash flow guidance remains at $375 million to $400 million for the year.

Margin Recovery Expected in the Second Half

Management still sees operating margin expanding by about 120 to 150 basis points in 2026, with most of the improvement weighted to the second half. For the second quarter, they expect reported revenue to decline mid- to high-single digits, organic revenue to dip only low-single digits and EPS to climb at least 30% sequentially from the first quarter’s $2.06.

Q1 Operating Margin Under Pressure

Despite the positive long-term tone, non-GAAP operating margin fell 280 basis points year-over-year to 16.3% in the first quarter. The drop was driven by higher stock-based compensation tied to leadership changes, elevated non-human primate sourcing costs and the timing of related study starts, along with lower NHP-related revenue in the Research Models and Services unit.

Earnings Per Share Decline but Beat Expectations

Non-GAAP earnings per share came in at $2.06, down 12% from the prior-year period as cost pressures more than offset modest top-line growth. Even so, the result slightly exceeded management’s prior outlook for the quarter, helped by initial benefits from cost actions and tighter expense control.

RMS Segment Hit by Model and NHP Weakness

The Research Models and Services segment struggled, with revenue of $208 million declining 5.5% organically from a year earlier. RMS operating margin contracted 240 basis points to 24.7%, as the business faced timing-related delays in NHP shipments and softer demand for small models in North America, partially offset by stronger trends in China.

DSA Feels Impact of Study Costs and Site Consolidation

DSA revenue slipped 1.4% organically in the quarter, reflecting a pause in growth as clients digested prior spending and as the company worked through site consolidations. The DSA operating margin dropped 290 basis points to 21.0%, pressured by higher study-related direct costs, including elevated NHP sourcing expenses and more study starts.

Free Cash Flow Dragged by Bonus Timing

Free cash flow turned negative in the quarter at minus $15 million, a $127 million swing from the prior year primarily tied to the timing of performance-based cash bonus payments. Management emphasized that this was a timing issue and reiterated full-year free cash flow guidance, suggesting underlying cash generation should improve as the year progresses.

Corporate Costs Elevated by Stock Compensation

Unallocated corporate expenses climbed to $63 million, or 6.4% of revenue, compared with 5.3% a year ago. The increase largely reflected the timing of stock compensation linked to the CEO transition, and the company continues to expect corporate costs to average about 5.5% of revenue for the full year.

FX and Divestitures Weigh on Reported Revenue

The outlook for reported revenue tightened as the company incorporated a stronger U.S. dollar and the impact of portfolio pruning. Management estimated divestitures would trim reported revenue guidance by roughly 500 basis points, and together with currency shifts, this led to a projected reported decline of 4.0% to 5.5% in 2026 even as underlying organic trends stabilize.

Legacy CDMO Loss and Higher Interest Costs

A previously disclosed loss of a large commercial CDMO client continued to weigh on Manufacturing growth, reducing segment organic growth by about 350 basis points in the quarter. While the CDMO business has now been divested, net interest expense for 2026 is expected to rise by roughly $8 million to a range of $103 million to $108 million due to short-term borrowings used to fund the $200 million share repurchase.

Guidance Underlines Second-Half Rebound Narrative

Forward-looking commentary centered on margin recovery and cash generation in the back half of 2026, underpinned by strong DSA bookings, a record backlog and significant cost savings. Management expects the second half operating margin to be more than 500 basis points higher than the first six months, with Q2 EPS projected to jump at least 30% sequentially, reinforcing a narrative of near-term turbulence but improving momentum into year-end.

Charles River’s earnings call left investors weighing short-term earnings and cash softness against tangible progress on portfolio focus, cost discipline and capital deployment. While early-year results reflect meaningful margin pressure and sluggish organic growth, the company’s reaffirmed guidance, growing backlog and second-half weighting of margin expansion suggest management sees the current reset as a staging point for a more profitable growth profile ahead.